The Center of Excellence was launched in July, in order to support increasing demand for oncology research studies. As Outsourcing-Pharma.com reported at the time, the USDA-certified facility features multiple holding rooms and dedicated procedure and formulation spaces.
The new services introduce various platforms for immuno-oncology program evaluation and new technologies for traditional oncology agents.
Globally, CrownBio has seen an increase in demand for its immuno-oncology services. As such, the company has made several previous additions to its offerings to include a collection of validated models and services for vivo pharmacodynamics and efficacy studies, including multi-color flow cytometry, immunohistochemistry, and multiplex ELISA.
According to the company, the newly expanded site will be able to provide avatar clinical trials (HuTrials™) with Humanized NSG™ xenografts.
The company has also developed new PDX derived cell lines to supplement its PrimePanel™ collection and has developed expanded 3D-tumor growth assays (3D-TGA) for most indications.